[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lindenhofgruppe AG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100634804","what-impact-does-an-initial-psycho-oncological-contact-have-on-people-with-cancer-100634804",false,"NCT07544446","What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?","The Impact of a Standardised Initial Contact by a Psycho-oncological Counsellor on Anxiety and Depression, Quality of Life and the Use of Psycho-oncological Support in Cancer Patients: A Patient-initiated Multicentre Randomised Controlled Study - the Psycho-oncological Initial Contact Study (PICS)","PICS","Inclusion Criteria:\n\n* Patients with an oncological disease diagnosed within the last 3 months with planned or ongoing systemic oncologic treatment (e.g. chemotherapy, immunotherapy, hormone therapy) or a planned or ongoing radiotherapy\n* Patient is ≥18 years of age and legally competent\n* Patients must have understood and signed the study information and the informed consent form\n* Patients are willing and able to complete scheduled follow-up evaluations \u002F questionnaires as described in the informed consent\n* No previous contact with psycho-oncological services\n\nExclusion Criteria:\n\n* Documented severe functional impairment according to the ECOG Performance Status (ECOG 3-4)\n* Patients receiving or planned to receive treatments associated with a severe risk of toxicity (e.g., CAR-T cell therapy, myeloablative therapy)\n* Insufficient language skills in German\n* Inability to give informed consent\n* Refusal to participate in the study, unsigned informed consent","ALL","18 Years",{"count":20,"type":21},148,"ESTIMATED","INTERVENTIONAL",[24],"NA","When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and\u002For in cases of high stress, seek psycho-oncological support.\n\nThis study investigates whether an initial consultation with a psycho-oncological specialist reduces anxiety and depression, improves quality of life, and whether patients subsequently make greater use of support services.\n\nParticipants will be randomised, meaning they will be assigned to groups at random to ensure that the results are comparable. In the intervention group, participants will receive a detailed initial consultation with a psycho-oncology specialist and standard treatment. In the control group, participants receive standard treatment. To gather results, questionnaires are administered at regular intervals (at the start, after 3 and 6 months). The study lasts a total of 6 months.\n\nThe study was developed by patients. It is being conducted simultaneously at several hospitals.",[27,28],"Cancer","Psycho-Oncology",[30,28,31,32,33,34,35,36],"cancer","Adults","anxiety and depression","quality of life","distress thermometer","systemic oncologic treatment","radiotherapy","NOT_YET_RECRUITING","2026-04-15",{"date":40,"type":41},"2026-04-22","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2028-12-31",{"name":47,"class":48},"Lindenhofgruppe AG","INDUSTRY",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100457603","comparison-of-radiographic-fusion-rate-and-clinical-outcome-of-alif-and-xlif-performed-with-either-recombinant-human-bone-morphogenetic-protein-2-or-vivigen-100457603","NCT05238740","Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®","Comparison of Radiographic Fusion Rate and Clinical Outcome of Anterior Lumbar and Extreme Lateral Interbody Fusion Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen® Cellular Bone Matrix, a Prospective Randomised Assessor Blind, Monocentric Trial","Inclusion criteria:\n\nPatients who have an indication for a monosegmental ALIF procedure on the L5\u002FS1 segment or a monosegmental XLIF procedure on L4\u002F5 (both ALIF and XLIF procedure with or without an additional pedicular stabilisation), e.g., treating conditions such as spondylosis, spondylolisthesis and degenerative disc disorders with back and\u002For leg pain\n\n* Patients must be 18 - 70 years of age\n* Patients must have understood and signed the study information and the informed consent form\n* Patients are willing and able to complete scheduled follow-up evaluations \u002F questionnaires as described in the Informed Consent\n\nExclusion criteria:\n\n* Patients under 18 years and over 70 years of age\n* Patients with tumour \u002F spine trauma \u002F known bone disease \u002F Parkinson's disease and similar CNS disorders \u002F diseases or injuries of the peripheral nerves\n* Other procedures or segment than mentioned in the inclusion citeriaAdditional planed spine surgeries after index surgery\n* Current smoking\n* Pregnant or breastfeeding patients (or patient planning a pregnancy within one year after surgery)\n* Insufficient language skills in German\n* Inability to give informed consent\n* Refusal to participate in the study, unsigned study consent\n* Participation in another interventional study within the 30 days preceding and during the present study","70 Years",{"count":59,"type":21},168,[24],"The aim of this study is to prospectively investigate the potential for bony fusion of ViviGen® bone graft substitute in comparison to rhBMP-2 in monosegmental ALIF procedure L5\u002FS1 and in monosegmental XLIF procedure L4\u002F5",[63,64,65],"Spondylosis","Spondylolisthesis","Degenerative Disc Disease",[67,68,69,70,63,64,65,71],"ViviGen","Radiographic fusion rate","Anterior lumbar interbody fusion","Recombinant human bone morphogenetic protein-2","Extreme lateral interbody fusion","RECRUITING","2025-06-04",{"date":75,"type":41},"2025-06-08",{"date":77,"type":41},"2022-10-27",{"date":79,"type":21},"2027-12",{"name":47,"class":48},1,""]